We found no reason to change current treatment recommendations. However, considerable uncertainty continues to exist about the optimal schedule for desferrioxamine in people with transfusion-dependent thalassaemia.
Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.